Request Discount

Hemophilia Treatment Drugs Market (Drug Class - Desmopressin, Antifibrinolytic Agents, Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, and Fibrin Sealants; Disease Indication - Hemophilia A, Hemophilia B, and Others; Distribution Channel - E-commerce, Retail Pharmacies, and Hospital Pharmacies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2026

  • Published : September, 2020

  • Rep Id : HC0477

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on the hemophilia treatment drugs market provides an in-depth analysis of segments and sub-segments in the global as well as regional hemophilia treatment drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional hemophilia treatment drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast, and dollar values of the global hemophilia treatment drugs market. According to the report, the global hemophilia treatment drugs market is projected to grow at a CAGR of 7.2% over the forecast period of 2020-2026.

 

Market Insight

Hemophilia is defined as a hereditary genetic disorder that damages the body’s ability to control blood clotting or coagulation. This leads to abnormal external and internal bleeding after injuries. The most common hemophilia seen in patients are hemophilia A and B. Hemophilia A arises when clotting factor VIII is reduced while hemophilia B arises when clotting factor IX is decreased. Even if both hemophilia is having similar symptoms and signs they are caused by mutations in diverse genes. Both A and B hemophilia can be mild, moderate, or severe, which depends on the amount of clotting factor that is in the blood. As per the Center for Disease Control and Prevention, Hemophilia A affects 1 in 5,000 male births and about 400 babies are born with hemophilia each year.  

 

 Increasing awareness regarding hemophilia is driving the growth of the hemophilia treatment drugs market. Government and organizations along with manufacturers of hemophilia drugs are concentrating on worldwide campaigns to generate consciousness regarding hemophilia among the population that is anticipated to upsurge the diagnosis rate for hemophilia. Further, with the support of the World Federation of Hemophilia (WFH) and domestic policies, hemophilia care in emerging countries is developing gradually. Additionally, several companies in the hemophilia treatment drugs market are collaborating with each other and along with research, organizations are developing new drugs in order to treat current and future unmet hemophilia conditions. Moreover, the life expectancy of people with hemophilia has also grown due to the advancements in medical science and the growing availability of safer treatment options. In the 1900s, patient life expectancy was only about 13 years whereas, by the 1960’s it had improved to about age 20.2, and today, a baby born with hemophilia in one of the advanced economies can expect to live a normal lifespan with the advanced treatment. This increasing life expectancy for hemophiliacs coupled with the lifelong nature of the disease will drive the growth of the hemophilia treatment drug market over the forecast period. Advancement in technology and the growth of novel coagulating factors are also some of the supporting factors for the growth of the hemophilia treatment drugs market. Moreover, advancement in gene therapy and drugs approved for treatment in hemophilia is likely to create growth opportunities in this market during the upcoming year. On the flip side, lack of awareness regarding these diseases in developing the region and the high cost associated with the treatment are hampering the growth of the market.

 

 In terms of geographies, North America dominated the growth of the hemophilia treatment drugs market followed by Europe and the Asia Pacific region. In North America region technological advancement, rising occurrence of hemophilia diseases, increasing investment in R&D activities for development in hemophilia drugs, and the growing practice of the recombinant product drivers the growth of this market. In the Europe region growing government support, rising occurrence of hemophilia A and upsurge in investment in innovation of new hemophilia products are positively supporting the growth of the hemophilia treatment drugs market. Further, in the Asia Pacific region due to increasing awareness about hemophilia diseases, development in healthcare sectors, increasing spending on healthcare and growing population are boosting factors for this market in the Asia Pacific region.

 

Segment Covered

The report on global hemophilia treatment drugs market covers segments such as drug class, disease indication, and distribution channel. On the basis of drug class, the sub-markets include desmopressin, antifibrinolytic agents, recombinant coagulation factor concentrates, plasma derived coagulation factor concentrates, and fibrin sealents. On the basis of disease indication, the sub-markets include hemophilia A, hemophilia B, and others. On the basis of distribution channel, the sub-markets include e-commerce, retail pharmacies, and hospital pharmacies.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Takeda Pharmaceutical Company Ltd, Biotest Aktiengesellschaft, Sanofi S.A., Bayer AG, Pfizer Inc., CSL Limited, Octapharma AG, F. Hoffmann-La Roche AG, Novo Nordisk A/S, and Kedrion S.p.A.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of hemophilia treatment drugs market. Moreover, the study highlights current market trends and provides forecast from 2020-2026. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount